AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high ...

In the second hour of "Connections with Evan Dawson" on 4/1/25, we discuss new treatments for Parkinson's disease with local experts and explore how to best support those living with the disease.

Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease.

A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day. About Anavex Life ...

People with inflammatory bowel disease (IBD) or Parkinson’s disease have depletions in similar types of beneficial bacteria, ...

An experimental drug has shown promise in preventing Alzheimer’s for ... which causes an overproduction of amyloid in the ...

From family members, to friends, to beloved members of society, Parkinson’s disease impacts more than 10 million people ...

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...

Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist the treatment.